Nicotinic Acid - The Underused Ally in the Fight against Coronary Disease

Abstract

Get full access to this article

View all access options for this article.

References

Johansson

Egberg

Asplund-Carlson

Carlson

: Nicotinic acid treatment shifts the fibrinolytic balance favourably and lowers plasma fibrinogen in hypertriglyceridemic men J Cardiovasc Risk 1997, 4:165–171.

Thompson

Kienast

Pyke

Haverkate

Van De Loo

: Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris N Engl J Med 1995, 332:635–641.

Wild

Fortmann

Marcovina

: A prospective case-control study of lipoprotein(a) levels and apo(a) size and risk of coronary heart disease in Stanford Five-City Project participants Arterioscler Thromb 1997, 17:239–245.

Mussoni

Mannucci

Sirtori

Camera

Maderna

Sironi

: Hypertryglyceridemia and regulation of fibrinolytic activity Arterioscler Thromb 1992, 12:19–27.

Broijersen

Eriksson

Wiman

Angelin

Hjerndahl

: Gemfibrozil treatment of combined hyperlipoproteinemia: No improvement on fibrinolysis despite marked reduction of plasma triglyceride levels Arterioscler Thromb 1996, 16:511–516.

Iacoviello

Amore

Curtis

Tacconi

Gaetano

Cerletti

: Modulation of fibrinolytic response to venous occlusion in humans by a combination of low-dose aspirin and n-3 polyunsaturated fatty acids Arterioscler Thromb 1992, 12:1191–1197.

Spannagl

Drummer

Froschl

Schacky

Landgraf-Leurs

Landgraf

: Plasmatic factors of haemostatis remain essentially unchanged except for PAI activity during n-3 fatty acid intake in type I diabetes mellitus Blood Coagul Fibrinolysis 1991, 2:259–265.

Grundy

: Small LDL, atherogenic dyslipidemia, and the metabolic syndrome Circulation 1997, 95:1–4.

O'Keefe

Jr Conn

Lavie

Jr Bateman

: The new paradigm for coronary artery disease: Altering risk factors, atherosclerotic plaques, and clinical prognosis Mayo Clin Proc 1996, 71:957–965.

10.

Rosenson

: Beyond low-density lipoprotein cholesterol: A perspective on low high-density lipoprotein disorders and Lp(a) lipoprotein excess Arch Intern Med 1996, 156:1278–1284.

11.

Lamarche

Tchernof

Moorjani

Cantin

Dagenais

Lupien

: Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men Circulation 1997, 95:69–75.

12.

Hamsten

Wiman

de Faire

Blomback

: Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction N Engl J Med 1985, 313:1557–1563.

13.

Jeppesen

Hein

Suadicani

Gyntelberg

: Relation of high TG-low HDL cholesterol and LDL cholesterol to the incidence of ischemic heart disease Arterioscler Thromb 1997, 17:1114–1120.

14.

O'Keefe

Jr Nelson

Harris

: Lifestyle change for coronary artery disease Postgrad Med 1996, 99:89–105.

15.

Superko

: Beyond LDL-C reduction Circulation 1996, 94:2351–2354.

16.

Scandinavian Simvastatin Survival Study Group: Randomised trial of cholesterol lowering in 4444 patients with coronary artery disease. The Scandinavian Simvastatin Survival Study (4S) Lancet 1994, 344:1383–1389.

17.

Illingworth

Stein

Michel

Dujovas

Frost

Knopp

: Comparative effects of lovastatin and niacin in primary hypercholesterolemia: A prospective trial Arch Intern Med 1994, 154:1586–1595.

18.

O'Keefe

Jr Harris

Nelson

Windsor

: Effects of pravastatin with niacin or magnesium on lipid levels and postprandial lipemia Am J Cardiol 1995, 76:480–484.

19.

Mckenney

Proctor

Harris

Chinchill

: A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients JAMA 1994, 271:672–677.

20.

Garg

Malinow

Pettinger

Hunninghake

: Treatment with niacin increases plasma homocysteine levels [abstract] Circulation 1996, 94:1–457.

21.

Graham

Daly

Refsum

Robinson

Brattstrom

Ueland

: Plasma homocysteine as a risk factor for vascular disease JAMA 1997, 277:1775–1781.

22.

Gupta

Dennis

Green

Jacobsen

Arheart

Robinson

: High homocysteine concentration, a risk factor for atherosclerotic complications of end stage renal disease, may be normalized by high doses of folic acid Am J Cardiol 1994, 29 (suppl A):43A.

23.

Canner

Berge

Wenger

Stamler

Friedman

Prineas

: Fifteen year mortality in coronary drug project patients: Long-term benefit with niacin J Am Coll Cardiol 1986, 8:1245–1255.

24.

Carlson

Rosenhamer

: Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid Acta Med Scand 1988, 233:405–418.

25.

Brown

Albers

Fisher

Schaefer

Lin

J-T

Kaplan

: Regression of coronary disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein N Engl J Med 1990, 323:1289–1298.

26.

Colquhoun

Hicks

Glasziou

: Comparative meta-analysis of 6 statin and 9 non-statin coronary regression trials. Evidence that cholesterol lowering is the key to outcomes Circulation 1996, 94:1–579.

27.

Mostaza

Schulz

Vega

Grundy

: Comparison of pravastatin with crystalline nicotinic acid monotherapy in treatment of combined hyperlipidemia Am J Cardiol 1997, 79:1298–1301.

28.

Davignon

Roederer

Montigny

Hayden

Tan

Connelly

: Comparative efficacy and safety of pravastatin, nicotinic acid and the two combined in patients with hypercholesterolemia Am J Cardiol 1994, 73:339–345.